WOODCLIFF LAKE, N.J., July 22 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced thatPatrick J. Zenner has been elected to the company's board of directors. Mr. Zenner was also appointed to the Compensation and Management Development Committee and the Corporate Development Review Committee.
Patrick G. LePore, Par's Chairman, Chief Executive Officer, and President, said, "I am very pleased to welcome an executive of Pat's caliber to our board. He has a detailed knowledge of the pharmaceutical industry and has extensive board experience. We look forward to working with him and benefiting from his substantial knowledge and leadership skills."
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.
SOURCE Par Pharmaceutical Companies, Inc.
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All